Every week, HealthXL communities connect to tackle the challenges in digital health. If you missed any of these meetings, here are some key takeaways from the past couple of weeks.
Do’s and don’ts when approaching investors with DTx
Know the investor and the planned exit. For some investors, the evidence generation and regulatory path for a company will be vital, particularly if there is any potential to be acquired by a life sciences company. Different types of investors will have different approaches and want different things, particularly when a company is dealing with both angel and venture investors.
Proving DTx efficacy and safety
The commercial and evidence generation strategies of digital therapeutics (DTx) should always be aligned. There is often a mismatch between the commercial strategy and the clinical studies, which leads to a situation where the clinical studies are not what the commercial team needs when reaching their clients (e.g. payers). Unfortunately, commercial and clinical tems speak different languages, making this strategy alignment difficult.
Demystifying Health Coaching in Digital Health Offerings
There are still a lot of misunderstandings about what health coaches actually do. They are more than merely ‘nudgers’, but a group that can work closely with someone to look at their underlying motivation and their broader approach to health.
If you have any questions or suggestions on how we can improve our content and your experience with HealthXL, please email [email protected]
